<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:og="http://ogp.me/ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" version="2.0" xml:base="http://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/medwatch/rss.xml">
  <channel>
    <title>MedWatch Safety Alerts RSS Feed</title>
    <link>http://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/medwatch/rss.xml</link>
    <description/>
    <language>en</language>
    
    <item>
  <title>2019 Medical Device Recalls</title>
  <link>http://www.fda.gov/medical-devices/medical-device-recalls/2019-medical-device-recalls</link>
  <description>The list below contains recalls that were issued in 2019.</description>
  <pubDate>Wed, 30 Oct 2019 10:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/medical-device-recalls/2019-medical-device-recalls</guid>
    </item>
<item>
  <title>ICU Medical, Inc. Issues a Voluntary Nationwide Recall of Lactated Ringer's Injection, USP and 0.9% Sodium Chloride Injection, USP Due to Presence of Particulate Matter</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/icu-medical-inc-issues-voluntary-nationwide-recall-lactated-ringers-injection-usp-and-09-sodium</link>
  <description>ICU Medical, Inc. (Nasdaq: ICUI) is voluntarily recalling one single lot of Lactated Ringer's Injection, USP, and one single lot of 0.9% Sodium Chloride Injection, USP. The products are being recalled to the hospital level due to the presence of particulate matter. </description>
  <pubDate>Wed, 30 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/icu-medical-inc-issues-voluntary-nationwide-recall-lactated-ringers-injection-usp-and-09-sodium</guid>
    </item>
<item>
  <title>Ethicon Recalls ECHELON FLEX™ ENDOPATH® Staplers for Failure to Completely Form Staples</title>
  <link>http://www.fda.gov/medical-devices/medical-device-recalls/ethicon-recalls-echelon-flextm-endopathr-staplers-failure-completely-form-staples</link>
  <description>Some ECHELON FLEX ENDOPATH staplers may contain an out of specification component, which may cause malformed staples, which may cause patient injury or death. </description>
  <pubDate>Wed, 30 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/medical-device-recalls/ethicon-recalls-echelon-flextm-endopathr-staplers-failure-completely-form-staples</guid>
    </item>
<item>
  <title>Update on Risk of Type III Endoleaks with Use of Endologix AFX Endovascular AAA Graft Systems: FDA Safety Communication</title>
  <link>http://www.fda.gov/medical-devices/safety-communications/update-risk-type-iii-endoleaks-use-endologix-afx-endovascular-aaa-graft-systems-fda-safety</link>
  <description>The FDA is evaluating new information about the risk of blood continuing to leak into the aneurysm (Type III endoleak) with Endologix AFX.</description>
  <pubDate>Mon, 28 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/safety-communications/update-risk-type-iii-endoleaks-use-endologix-afx-endovascular-aaa-graft-systems-fda-safety</guid>
    </item>
<item>
  <title>Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-pharmaceuticals-initiates-voluntary-nationwide-recall-one-lot-alprazolam-tablets-usp-c-iv-05</link>
  <description>Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level. This lot is being recalled due to the potential presence of foreign substance</description>
  <pubDate>Sat, 26 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-pharmaceuticals-initiates-voluntary-nationwide-recall-one-lot-alprazolam-tablets-usp-c-iv-05</guid>
    </item>
<item>
  <title>Novitium Pharma Issues Voluntary National Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA)</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg</link>
  <description>Voluntarily recalling all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules in the US to the consumer level. Ranitidine Hydrochloride Capsules are being recalled because of potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. </description>
  <pubDate>Fri, 25 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg</guid>
    </item>
<item>
  <title>Lannett Issues Voluntary Nationwide Recall of Ranitidine Syrup (Ranitidine Oral Solution, USP), 15mg/ml due to an Elevated Level of the Unexpected Impurity, N-Nitrosodimethylamine (NDMA)</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/lannett-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral-solution-usp-15mgml-due</link>
  <description>Lannett Company, Inc. today announced that it is voluntarily recalling all lots within expiry of Ranitidine Syrup</description>
  <pubDate>Fri, 25 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/lannett-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral-solution-usp-15mgml-due</guid>
    </item>
<item>
  <title>Dr. Reddy’s Confirms its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market</link>
  <description>Nationwide recall on October 1, 2019, (at the retail level for over-the-counter products and at the consumer level for prescription products) of all of its ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by the FDA</description>
  <pubDate>Wed, 23 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market</guid>
    </item>
<item>
  <title>Sanofi Provides Update on Precautionary Voluntary Recall of Zantac OTC in U.S.</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us</link>
  <description>As a precautionary measure, Sanofi on Friday, October 18, intiated a voluntary recall of all Zantac OTC (over-the-counter) in the United States. This includes Zantac 150®, Zantac 150® Cool Mint, and Zantac 75®. </description>
  <pubDate>Wed, 23 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us</guid>
    </item>
<item>
  <title>Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the Product</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n</link>
  <description>As a precautionary measure, Perrigo Company plc announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). The recall is being taken due to possible presence of a nitrosamine impurity called N-nitrosodimethylamine (NDMA). </description>
  <pubDate>Wed, 23 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n</guid>
    </item>
<item>
  <title>GL Holdings Issues Voluntary Worldwide Recall of Green Lumber Products Due to Presence of Undeclared Tadalafil</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gl-holdings-issues-voluntary-worldwide-recall-green-lumber-products-due-presence-undeclared</link>
  <description>GL Holdings is voluntarily recalling six lots of Green Lumber 2-, 4-, and 10-capsule packages purchased on or before August 10, 2019 to the consumer level. FDA analysis has found one lot of Green Lumber distributed between June and August 2019 to be tainted with tadalafil.</description>
  <pubDate>Tue, 22 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gl-holdings-issues-voluntary-worldwide-recall-green-lumber-products-due-presence-undeclared</guid>
    </item>
<item>
  <title>2019 Biologics Recalls</title>
  <link>http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/2019-biologics-recalls</link>
  <description>2019 Biologics Recalls&lt;div class="table-responsive"&gt;&lt;br /&gt;
  &lt;table class="table table-bordered" summary="2019 Biologics Recalls"&gt;&lt;br /&gt;
    &lt;thead&gt;&lt;br /&gt;
      &lt;tr&gt;&lt;br /&gt;
        &lt;th scope="col"&gt;Date Notification&lt;br /&gt;
        &lt;/th&gt;&lt;br /&gt;
        &lt;th scope="col"&gt;Brand Name&lt;br /&gt;
        &lt;/th&gt;&lt;br /&gt;
        &lt;th scope="col"&gt;Product Description&lt;br /&gt;</description>
  <pubDate>Wed, 16 Oct 2019 10:50:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/2019-biologics-recalls</guid>
    </item>
<item>
  <title>Important Drug Information - Humate-P [Antihemophilic Factor/von Willebrand Factor Complex (Human)]</title>
  <link>http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/important-drug-information-humate-p-antihemophilic-factorvon-willebrand-factor-complex-human</link>
  <description>CSL Behring LLC is alerting customers to a misalignment in the printing of the data on the folding box of Humate-P  that might lead to confusion of the user.</description>
  <pubDate>Wed, 16 Oct 2019 09:50:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/important-drug-information-humate-p-antihemophilic-factorvon-willebrand-factor-complex-human</guid>
    </item>
<item>
  <title>Viatrexx Bio Incorporated Issues Voluntary Nationwide Recall of Sterile Injectables Due to a Lack of Sterility Assurance</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/viatrexx-bio-incorporated-issues-voluntary-nationwide-recall-sterile-injectables-due-lack-sterility</link>
  <description>Viatrexx Bio Incorporated, Newark, Delaware is voluntarily recalling 10 mL sterile injectable vials of products, listed in the table below with lot numbers, to the consumer level. The products were sold exclusively to practitioners for office use. The products were manufactured in a manner that cann</description>
  <pubDate>Tue, 15 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/viatrexx-bio-incorporated-issues-voluntary-nationwide-recall-sterile-injectables-due-lack-sterility</guid>
    </item>
<item>
  <title>Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of all Sterile Compounded Drug Products Due to a Lack of Sterility Assurance</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/innoveix-pharmaceuticals-inc-issues-voluntary-recall-all-sterile-compounded-drug-products-due-lack</link>
  <description>Innoveix Pharmaceuticals, Inc. is voluntarily recalling all sterile compounded drug products, within expiry, to the consumer level. The products are being recalled due to a lack of assurance of sterility. These concerns arose following a routine inspection of the pharmacy by FDA.</description>
  <pubDate>Thu, 10 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/innoveix-pharmaceuticals-inc-issues-voluntary-recall-all-sterile-compounded-drug-products-due-lack</guid>
    </item>
<item>
  <title>ICU Medical Issues a Voluntary Nationwide Recall of Certain Lots of Plum and Sapphire Microbore Infusion Sets with Inline Filters</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/icu-medical-issues-voluntary-nationwide-recall-certain-lots-plum-and-sapphire-microbore-infusion</link>
  <description>ICU Medical, Inc. announced a voluntary recall on 29 July 2019 of certain lots of Plum and Sapphire Microbore Infusion Sets with inline filters due to the potential for small amounts of fluid leaking out of the air vents on the inline filters. To date, ICU Medical is not aware of adverse events rela</description>
  <pubDate>Tue, 08 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/icu-medical-issues-voluntary-nationwide-recall-certain-lots-plum-and-sapphire-microbore-infusion</guid>
    </item>
<item>
  <title>Medtronic Recalls 6 French Sherpa NX Active Guide Catheters Due to Separation and Fragmentation Issue</title>
  <link>http://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-6-french-sherpa-nx-active-guide-catheters-due-separation-and-fragmentation-issue</link>
  <description>Medtronic is recalling the 6 French Sherpa NX Active Guide Catheter due to a risk of the outer material separating from the device resulting in detached fragments that could result in the underlying stainless-steel braid wires being exposed.</description>
  <pubDate>Tue, 08 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-6-french-sherpa-nx-active-guide-catheters-due-separation-and-fragmentation-issue</guid>
    </item>
<item>
  <title>Lung Injury Update: FDA Warns Public to Stop Using Tetrahydrocannabinol (THC)-Containing Vaping Products and Any Vaping Products Obtained Off the Street   </title>
  <link>http://www.fda.gov/safety/medical-product-safety-information/lung-injury-update-fda-warns-public-stop-using-tetrahydrocannabinol-thc-containing-vaping-products</link>
  <description>FDA is strengthening its warning to consumers to stop using vaping products containing THC amid more than 1,000 reports of lung injuries—including some resulting in deaths—following the use of vaping products.</description>
  <pubDate>Fri, 04 Oct 2019 14:17:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/medical-product-safety-information/lung-injury-update-fda-warns-public-stop-using-tetrahydrocannabinol-thc-containing-vaping-products</guid>
    </item>
<item>
  <title>CBER FY 2019 Recall Postings</title>
  <link>http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2019-recall-postings</link>
  <description>Listing of CBER FY 2019 Recall Postings</description>
  <pubDate>Wed, 02 Oct 2019 07:15:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2019-recall-postings</guid>
    </item>
<item>
  <title>CBER FY 2018 Recall Postings</title>
  <link>http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2018-recall-postings</link>
  <description>List of CBER FY 2018 Recall Postings.</description>
  <pubDate>Wed, 02 Oct 2019 07:15:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2018-recall-postings</guid>
    </item>

  </channel>
</rss>
